Analyst consensus rating
Dogwood Therapeutics Analyst Rating: none
Direct answer
Dogwood Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.00.
Forecast evidence checked November 22, 2026.
Get free Dogwood Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.04
- Average price target
- $14.00
- High price target
- $15.00
- Low price target
- $12.00
- Low target gap
- +1,059.4%
- Target upside
- +1,252.7%
- High target gap
- +1,349.3%
- Target range width
- 289.9%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 22, 2026
- Valid through
- November 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Dogwood Therapeutics?
Dogwood Therapeutics has a verified none consensus. The same dataset has an average price target of $14.00.
How far are Dogwood Therapeutics's low and high targets from the recorded price?
The low target implies +1,059.4%, while the high target implies +1,349.3%.
How many analysts are included in Dogwood Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Dogwood Therapeutics's target upside or downside calculated?
The average target of $14.00 is divided by the recorded price of $1.04, then one is subtracted to produce +1,252.7%. This does not guarantee a future return.
When was Dogwood Therapeutics's analyst forecast verified?
The data was verified on 2026-11-22. The dataset is valid through 2026-11-29.